Sequenom, Inc. (NASDAQ:SQNM) Received Premarket Clearance From The USFDA

Boston, MA 06/17/2014 (wallstreetpr) – Sequenom, Inc. (NASDAQ:SQNM) on June 16, 2014 announced that the United States Food and Drug Administration (FDA) gave premarket 510(k) clearance to market the company’s IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx(TM) System. What Is IMPACT Dx Factor V Leiden And Factor II […]

Sequenom, Inc. (NASDAQ:SQNM) Notifies IMPACT DX System And Others

Boston, MA 10/18/2013 (wallstreetpr) – Sequenom, Inc. (NASDAQ:SQNM) an innovator in the clinical research and clinical molecular diagnostic instrumentation, technology and tests has notified two of its latest products: “IMPACT Dx™ System and its IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test” with FDA, in early October. Both the system and the test are […]